Patient and disease characteristics in a small CAD cohort
A retrospective analysis hints at the wide range of cold agglutinin disease (CAD) clinical behavior. Koudouna et al. investigated the characteristics of 8 patients with CAD at the time of diagnosis [1]. Median age was 62 years, and 5 patients were women. Hematologic malignancies constituted 50 % of underlying medical conditions; in 37 %, hepatitis B/C was the associated disease, and in 13 %, autoimmune disorders. The median hemoglobin level at presentation was 8.9 g/dL. Slightly elevated serum CRP and ferritin levels represented common findings. All patients had cold-sensitive antibodies, with one also showing cryoglobulins. Cold agglutinins titers were disproportionate to the degree of hemolysis in 4 patients with underlying lymphoproliferative disorders. Low serum monoclonal IgM prevailed in 4 cases even in the presence of hypogammaglobulinemia. Fatigue dominated among symptoms, followed by hepatomegaly and jaundice, skin complications, and splenomegaly. The patient who had cryoglobulinemia showed skin necrosis due to vascular occlusion.
All patients initially received corticosteroids. Complete or partial responses were observed in 3 patients with primary CAD treated with corticosteroids, splenectomy and mycophenolate mofetil. Additional approaches included plasma exchange and anti-CD20 therapy. In 5 cases, additional treatment for the underlying disease was administered. During a median follow-up of 42.5 months, 2 patients died from infection and sepsis, while another 2 completely recovered and the remaining patients experienced relapses and remissions.
REFERENCES
- Koudouna A et al., Report on cold agglutinin disease patients’ clinical characteristics. EHA 2020, abstract EP1688
More posts
Patient and disease characteristics in a small CAD cohort
A retrospective analysis hints at the wide range of cold agglutinin disease (CAD) clinical behavior. Koudouna et al. investigated the characteristics of 8 patients with CAD at the time of diagnosis [1]. Median age was 62 years, and 5 patients were women. Hematologic malignancies constituted 50 % of underlying medical conditions; in 37 %, hepatitis B/C was the associated disease, and in 13 %, autoimmune disorders.
Cold agglutinin disease: on the road to new insights and potential treatment options
Cold agglutinin disease (CAD) is a rare type of autoimmune hemolytic anemia (AIHA) elicited by cold-sensitive antibodies including cold agglutinins. Ninety percent of cold agglutinins belong to the IgM kappa category and bind to red blood cell surface antigens at temperatures of ≤ 37 °C, thus inducing hemolysis.
Paroxysmal nocturnal hemoglobinuria: improving outcomes with novel strategies
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, potentially life-threatening clonal hematopoietic stem cell disorder characterized by hemolytic anemia, bone marrow failure, thrombosis, and peripheral blood cytopenia. The disease results from an acquired loss-of-function mutation of the PIGA gene involved in the synthesis of the glycosylphosphatidylinositol-anchored complement inhibitors CD55 and CD59.
Targeted approaches in various B-cell malignancies
BTK inhibitors are active in many B-cell malignancies such as mantle cell lymphoma, CLL and Waldenström’s macroglobulinemia, but also in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). Zanubrutinib is currently being assessed in pivotal phase II and III studies in all of these indications.
Changing paradigms in the management of mantle cell lymphoma
Mantle cell lymphoma (MCL) is a rare, heterogenous and generally aggressive subtype of B-cell non-Hodgkin lymphoma that remains incurable in the majority of cases. Median survival in non-trial patients has been estimated at 3 to 5 years. First-line therapy usually consists of chemoimmunotherapy, while both immunochemotherapy and targeted agents are recommended in relapsed disease.
Optimizing timing, efficacy and tolerability in chronic lymphocytic leukemia
In both treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), inhibition of Bruton’s tyrosine kinase (BTK) represents a treatment standard as it has improved clinical outcomes. Compared to the first-generation agent ibrutinib, the second-generation, highly selective BTK inhibitor acalabrutinib shows minimal off-target kinase inhibition, thus potentially offering an optimized safety profile.
